Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Camurus AB
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patient ≥18 years old
Histologically confirmed, advanced (unresectable and/or metastatic), and well-differentiated NET of GEP or presumed GEP origin
At least 1 measurable, somatostatin receptor-positive lesion according to RECIST 1.1 determined by multiphasic CT or MRI (performed within 28 days before randomization)
ECOG performance status of 0 to 2
You may not be if
Documented evidence of disease progression while on treatment (including SSAs) for locally advanced unresectable or metastatic disease
Known central nervous system metastases
Consecutive treatment with long-acting SSAs for more than 6 months before randomization
Carcinoid symptoms that are refractory to treatment (according to the Investigator's judgement) with conventional doses of octreotide LAR or lanreotide ATG and/or to treatment with daily doses of ≤600 µg of octreotide IR
Previous treatment with more than 1 cycle of targeted therapies such as mTOR inhibitors or vascular endothelial growth factor inhibitors, or more than 1 cycle of chemotherapy or interferon for GEP-NET
Treatment of GEP-NET with trans-arterial chemoembolization or trans-arterial embolization within 12 months before screening
Previously received radioligand therapy (PRRT) at any time
Clareo Health | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
